Expert Review of Hematology

Papers
(The H4-Index of Expert Review of Hematology is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Are we closer to a standard of care for Richter’s syndrome? Novel treatments on the horizon54
Hemophagocytic lymphohistiocytosis in Egyptian children: diagnosis, treatment challenges, and outcome53
Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management43
Do we need more guidance on thrombophilia testing? Challenges and special considerations36
Hematological parameters and X-ray exposure among medical radiation workers: a systematic review and meta-analysis34
A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly26
Frequencies of glycosylphosphatidylinositol (GPI)-deficient cells using high-sensitivity flow cytometry as per the 2018 ICCS/ESCCA consensus guideline in patients with hematologic malignancy, aplastic25
Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia25
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care23
Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma23
What is the future of digital tools to help manage pain in sickle cell disease patients?23
Treating sickle cell disease in resource-limited sub-Saharan Africa: recent strategies and recommendations in addressing the gaps for the provision of evidence-based management22
The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease21
COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis21
Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP21
Treatment patterns and blood count control in 10,112 patients with polycythemia vera21
Are myelodysplastic syndromes ready for venetoclax? Exploring future potential and considerations20
Correlation between hematocrit and the risk of common human cancers: results of a 1999–2020 observational survey and Mendelian randomization analysis19
Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: current status and future directions mainly focusing on a Chinese perspective18
0.079182863235474